MA-ANTERRA-CAPITAL
29.6.2021 14:02:13 CEST | Business Wire | Press release
Anterra Capital (“Anterra”), the international food and agriculture specialist venture capital firm, today announced the initial closing of its second food and agriculture technology fund, Anterra F&A Ventures II, raising $175 million, exceeding the targeted size of the fund. Due to the positive market reception for the fund’s mission and strategy, Anterra is tracking towards an upsized second fund, and anticipates a final closing in the third quarter, 2021.
Anterra’s unique investment approach has attracted commitments from a prestigious and aligned group of long-term oriented global investors, with continued support from Eight Roads Ventures, backed by Fidelity, and Rabo Investments, the captive investment arm of the largest global food and agricultural bank out of the Netherlands - Rabobank. New investors include Novo Holdings, a leading global life sciences investor based out of Denmark; Tattarang, one of Australia’s largest private investment groups and the holding company of the Forrest family’s private business interests; as well as other well-respected family offices, sovereign wealth funds, and state-owned investors that provide a global presence, spanning across multiple continents.
Anterra’s mission is to invest in and partner with entrepreneurs transforming our vital food economy through biotech and digital innovation across crop science, animal health, and human nutrition. As a research driven, value-focused specialist investor Anterra uniquely combines a traditional venture investment approach and “venture creation,” building and scaling transformative businesses with its deep industry knowledge and vast global network as a pioneer in the space. While investor interest is growing in the Food & Ag industry, early-stage investment in this essential segment significantly trails that of other key industries, for comparison, less than half of that in Pharma & Biotech (~$40 billion) and about a fifth of venture investment in Software (~$100 billion).
“The food economy is in critical condition, and new digital and biotech solutions are desperately needed in order to support better outcomes for farmers, consumers and the environment,” said Adam Anders, Managing Partner of Anterra Capital. “With the first close, we continue our mission to sustainably transform our food economy, building on our leadership position as an early-stage investor in markets such as plant and animal health, while actively expanding our investment activity across the food and agriculture value chain.”
Daniel Auerbach, Senior Managing Partner and Global Head of Eight Roads Ventures, one of Anterra’s original lead investors, added: “Within Food & Ag, Anterra sits at the intersection of life sciences and digital technology and our expanded investment reflects our confidence in Anterra’s mission, leadership and performance for us over the past eight years.”
“We are excited to partner with Anterra and support the fund’s transformational mission, which is aligned with our investment activity across the biotech space overall, and emphasizes our commitment to investing in innovation within Food & Agriculture,” said Kartik Dharmadhikari, a Partner of Novo Growth within Novo Holdings.
About Anterra
With offices in Amsterdam and Boston, Anterra Capital is an international specialist venture capital investor dedicated to financing the growth of technology-driven companies with incredible potential in food, agriculture, and animal health. Supported by multinational institutional investors, Anterra provides patient strategic capital to entrepreneurs and innovative companies sustainably transforming our global food system. Further information: www.anterracapital.com
About Eight Roads Ventures
Eight Roads Ventures is a global investment firm backed by Fidelity. Eight Roads Ventures manages $7bn of assets across its offices in China, Hong Kong, India, Japan, UK and the US. Our 50-year history of investing includes partnerships with over 300 companies such as Alibaba, AppsFlyer, BlackDuck, Chewy, Devoted Health, Flywire, Icertis, iPipeline, Kensho, Letgo, Made.com, Neo4j, Nuance, Paidy, Ping Identity, Pony.ai, PharmEasy, Shadowfax, Toast, Wallapop, WuXi PharmaTech, and Xoom. Further information: https://eightroads.com
About Novo Holdings A/S
Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information: http://www.novoholdings.dk
About Rabo Investments
Rabo Investments is Rabobank’s PE investment franchise. It has invested over €1.5 billion worldwide within the cutting-edge Food & Agri, Sustainability, and Healthcare sectors in the Netherlands and within the Food & Agri sector worldwide. The investments range from growth capital for innovative start-ups and scale-ups to investments in established companies and funds. Further information: https://raboinvestments.com
About Tattarang
Tattarang is one of Australia’s largest private investment groups and is owned by the Forrest family. Its diverse investment portfolio spans across agri-food, energy, resources, property and lifestyle. The group is made up of six business divisions including Harvest Road which is one of Australia’s largest and most diverse agricultural businesses with an expanding portfolio of high-quality foods. Further information: www.tattarang.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005357/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom